LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 25.03

Change

-0.21 (-0.83)%

Market Cap

N/A

Volume

2.80K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

-0.29 (-1.07%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.02%)

CAD 5.38B
XEQT:CA iShares Core Equity Portfolio

+0.07 (+0.21%)

CAD 5.22B
PHYS-U:CA Sprott Physical Gold Trust

-0.13 (-0.65%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.11 (+0.29%)

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.44 (+0.96%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

-0.13 (-0.54%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

-0.07 (-0.68%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.14 (-0.62%)

CAD 2.78B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

CAD 2.68B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.21% 31% F 34% F
Dividend Return 7.40% 90% A- 91% A-
Total Return 12.61% 43% F 44% F
Trailing 12 Months  
Capital Gain 7.66% 29% F 33% F
Dividend Return 8.95% 90% A- 90% A-
Total Return 16.60% 39% F 41% F
Trailing 5 Years  
Capital Gain 13.67% 46% F 49% F
Dividend Return 39.67% 91% A- 92% A
Total Return 53.34% 64% D 63% D
Average Annual (5 Year Horizon)  
Capital Gain 2.24% 51% F 44% F
Dividend Return 2.41% 51% F 37% F
Total Return 0.16% 65% D 18% F
Risk Return Profile  
Volatility (Standard Deviation) 5.60% 74% C 89% A-
Risk Adjusted Return 43.00% 64% D 59% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike